Harvard Bioscience Files 8-K on Security Holder Vote
Ticker: HBIO · Form: 8-K · Filed: May 14, 2024 · CIK: 1123494
| Field | Detail |
|---|---|
| Company | Harvard Bioscience Inc (HBIO) |
| Form Type | 8-K |
| Filed Date | May 14, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
Related Tickers: HBIO
TL;DR
Harvard Bioscience held a shareholder vote on May 14th. Details TBD.
AI Summary
On May 14, 2024, Harvard Bioscience, Inc. filed an 8-K report indicating that it submitted matters to a vote of its security holders. The filing does not specify the nature of the matters voted upon or the outcome of the vote.
Why It Matters
This filing signals that Harvard Bioscience held a shareholder meeting where important decisions were made, the details of which may impact the company's future direction.
Risk Assessment
Risk Level: low — The filing is a routine procedural report and does not contain information about significant financial changes or operational risks.
Key Players & Entities
- HARVARD BIOSCIENCE, INC. (company) — Registrant
- May 14, 2024 (date) — Date of earliest event reported
FAQ
What specific matters were submitted to a vote of Harvard Bioscience's security holders on May 14, 2024?
The filing states that matters were submitted to a vote of security holders, but it does not specify what those matters were.
What was the outcome of the vote by Harvard Bioscience's security holders?
The filing does not disclose the results or outcome of the vote.
Is this filing related to a specific corporate action, such as a merger or acquisition?
The filing indicates a submission of matters to a vote of security holders, which could be related to corporate actions, but the specific nature is not detailed in this report.
When was the report filed with the SEC?
The report was filed on May 14, 2024.
What is Harvard Bioscience, Inc.'s principal executive office address?
The principal executive offices are located at 84 October Hill Road, Holliston, MA 01746.
Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-05-14 17:20:43
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value HBIO The NASDAQ Stock Marke
Filing Documents
- f8k_051424.htm (8-K) — 26KB
- 0001171843-24-002878.txt ( ) — 194KB
- hbio-20240514.xsd (EX-101.SCH) — 3KB
- hbio-20240514_lab.xml (EX-101.LAB) — 33KB
- hbio-20240514_pre.xml (EX-101.PRE) — 22KB
- f8k_051424_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 14, 2024, Harvard Bioscience, Inc. (the " Company ") held its 2024 Annual Meeting of Stockholders, at which the Company's stockholders voted on three proposals that are described in detail in the Company's Definitive Proxy Statement filed with the Securities and Exchange Commission on April 3, 2024. The voting results for each of the proposals are reported below. Proposal 1 - Election of Director The Company's stockholders elected one Class III Director for a three-year term, such term to continue until the annual meeting of stockholders in 2027 and until such director's successor is duly elected and qualified or until his earlier resignation or removal. Name Votes For Votes Withheld Broker Non-Votes Alan Edrick 19,722,574 10,861,497 4,292,458 Proposal 2 –Ratification of the Appointment of Grant Thornton LLP The Company's stockholders ratified the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. There were no broker non-votes on this proposal. Votes For Votes Against Votes Abstained 34,794,995 73,003 8,531 Proposal 3 –Approval, by Non-Binding Advisory Vote, of the Compensation of the Named Executive Officers The Company's stockholders approved the compensation of the Company's named executive officers, by a non-binding advisory vote: Votes For Votes Against Votes Abstained Broker Non-Votes 27,472,149 903,608 2,208,314 4,292,458 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARVARD BIOSCIENCE, INC. Date: May 14, 2024 /s/ John Fry John Fry Chief Legal Counsel and Secretary